The Underestimated Relevance of Alzheimer's Disease Copathology in Amyotrophic Lateral Sclerosis

被引：5

作者：

Barba, Lorenzo ^{[1
]}

Otto, Markus ^{[1
]}

Abu-Rumeileh, Samir ^{[1
]}

机构：

[1] Martin Luther Univ Halle Wittenberg, Dept Neurol, Halle, Saale, Germany

来源：

JOURNAL OF ALZHEIMERS DISEASE | 2023年 / 95卷 / 04期

关键词：

Alzheimer's disease; amyloid-beta; amyotrophic lateral sclerosis; biomarker; copathology; neurofilament light chain; ANTISENSE OLIGONUCLEOTIDE TOFERSEN; TRIAL; RATIO;

D O I：

10.3233/JAD-230900

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Concomitant Alzheimer's disease (AD) pathology can be observed in approximately 10-15% of cases with amyotrophic lateral sclerosis (ALS). ALS-AD patients have a higher prevalence of amnestic cognitive disturbances, which may often precede motor symptoms. Cerebrospinal fluid (CSF) AD core biomarkers usually show no or slightly significant changes in ALS, whereas blood phosphorylated tau protein might be increased independently from AD copathology. Neurofilament proteins are consistently elevated in CSF and blood of ALS, but have been poorly investigated in ALS-AD. All these issues should be taken into account when using fluid biomarkers as inclusion criteria or secondary endpoints in clinical trials.

引用

页码：1401 / 1404

页数：4

共 29 条

[1] The multifaceted role of neurofilament light chain protein in non-primary neurological diseases [J].

Abu-Rumeileh, Samir ;

Abdelhak, Ahmed ;

Foschi, Matteo ;

D'Anna, Lucio ;

Russo, Michele ;

Steinacker, Petra ;

Kuhle, Jens ;

Tumani, Hayrettin ;

Blennow, Kaj ;

Otto, Markus .

BRAIN, 2023, 146 (02) :421-437

[2] Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis [J].

Abu-Rumeileh, Samir ;

Vacchiano, Veria ;

Zenesini, Corrado ;

Polischi, Barbara ;

de Pasqua, Silvia ;

Fileccia, Enrico ;

Mammana, Angela ;

Di Stasi, Vitantonio ;

Capellari, Sabina ;

Salvi, Fabrizio ;

Liguori, Rocco ;

Parchi, Piero .

JOURNAL OF NEUROLOGY, 2020, 267 (06) :1699-1708

[3] Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study [J].

Abu-Rumeileh, Samir ;

Mometto, Nicola ;

Bartoletti-Stella, Anna ;

Polischi, Barbara ;

Oppi, Federico ;

Poda, Roberto ;

Stanzani-Maserati, Michelangelo ;

Cortelli, Pietro ;

Liguori, Rocco ;

Capellari, Sabina ;

Parchi, Piero .

JOURNAL OF ALZHEIMERS DISEASE, 2018, 66 (02) :551-563

[4] Patterns of synaptic loss in human amyotrophic lateral sclerosis spinal cord: a clinicopathological study [J].

Aousji, Oumayma ;

Feldengut, Simone ;

Antonucci, Stefano ;

Schoen, Michael ;

Boeckers, Tobias M. ;

Matschke, Jakob ;

Mawrin, Christian ;

Ludolph, Albert C. ;

Del Tredici, Kelly ;

Roselli, Francesco ;

Braak, Heiko .

ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2023, 11 (01)

[5] Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias [J].

Baiardi, Simone ;

Quadalti, Corinne ;

Mammana, Angela ;

Dellavalle, Sofia ;

Zenesini, Corrado ;

Sambati, Luisa ;

Pantieri, Roberta ;

Polischi, Barbara ;

Romano, Luciano ;

Suffritti, Matteo ;

Bentivenga, Giuseppe Mario ;

Randi, Vanda ;

Stanzani-Maserati, Michelangelo ;

Capellari, Sabina ;

Parchi, Piero .

ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)

[6] Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias [J].

Baiardi, Simone ;

Abu-Rumeileh, Samir ;

Rossi, Marcello ;

Zenesini, Corrado ;

Bartoletti-Stella, Anna ;

Polischi, Barbara ;

Capellari, Sabina ;

Parchi, Piero .

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2019, 6 (02) :263-273

[7] CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease [J].

Barba, Lorenzo ;

Abu-Rumeileh, Samir ;

Halbgebauer, Steffen ;

Bellomo, Giovanni ;

Paolini Paoletti, Federico ;

Gaetani, Lorenzo ;

Oeckl, Patrick ;

Steinacker, Petra ;

Massa, Federico ;

Parnetti, Lucilla ;

Otto, Markus .

NEUROLOGY, 2023, 101 (01) :E50-E62

[8] Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study [J].

Benatar, Michael ;

Wuu, Joanne ;

Andersen, Peter M. ;

Bucelli, Robert C. ;

Andrews, Jinsy A. ;

Otto, Markus ;

Farahany, Nita A. ;

Harrington, Elizabeth A. ;

Chen, Weiping ;

Mitchell, Adele A. ;

Ferguson, Toby ;

Chew, Sheena ;

Gedney, Liz ;

Oakley, Sue ;

Heo, Jeong ;

Chary, Sowmya ;

Fanning, Laura ;

Graham, Danielle ;

Sun, Peng ;

Liu, Yingying ;

Wong, Janice ;

Fradette, Stephanie .

NEUROTHERAPEUTICS, 2022, 19 (04) :1248-1258

[9] Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis [J].

Cousins, Katheryn A. Q. ;

Shaw, Leslie M. ;

Shellikeri, Sanjana ;

Dratch, Laynie ;

Rosario, Luis ;

Elman, Lauren B. ;

Quinn, Colin ;

Amado, Defne A. ;

Wolk, David A. ;

Tropea, Thomas F. ;

Chen-Plotkin, Alice ;

Irwin, David J. ;

Grossman, Murray ;

Lee, Edward B. ;

Trojanowski, John Q. ;

McMillan, Corey T. .

ANNALS OF NEUROLOGY, 2022, 92 (05) :807-818

[10] Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis [J].

Gille, B. ;

De Schaepdryver, M. ;

Goossens, J. ;

Dedeene, L. ;

De Vocht, J. ;

Oldoni, E. ;

Goris, A. ;

Van Den Bosch, L. ;

Depreitere, B. ;

Claeys, K. G. ;

Tournoy, J. ;

Van Damme, P. ;

Poesen, K. .

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2019, 45 (03) :291-304

← 1 2 3 →